Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging

Biomaterials

Volumn 29, Issue 29, 2008, Pages 4012-4021

  Jain, Tapan K ^a   Richey, John ^b   Strand, Michelle ^c   Leslie Pelecky, Diandra L ^c   Flask, Chris A ^b   Labhasetwar, Vinod ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Anti proliferative effects; Anticancer agents; Imaging; Iron oxide; Tumor

Indexed keywords

ATOMS; CHEMOTHERAPY; DRUG DELIVERY; FERROMAGNETISM; HYDROGELS; IMAGING TECHNIQUES; IRON; IRON OXIDES; MAGNETIC FIELDS; MAGNETIC MATERIALS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; OLEIC ACID; RESONANCE; ZETA POTENTIAL;

ANTI-PROLIFERATIVE EFFECTS; ANTICANCER AGENTS; ANTIPROLIFERATIVE ACTIVITIES; DOXORUBICIN; DRUG INCORPORATION; DRUG RELEASES; FUNCTIONAL PROPERTIES; IMAGING; IRON OXIDE; MAGNETIC NANO-PARTICLES; MAGNETIZATION PROPERTIES; MARGINAL EFFECTS; MCF-7 BREAST CANCER CELLS; PACLITAXEL; PLURONIC; TUMOR; ZETA POTENTIALS;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; DOXORUBICIN; IRON OXIDE; NANOCARRIER; OLEIC ACID; PACLITAXEL; POLOXAMER; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CAROTID ARTERY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MATERIALS TESTING; MICE; MICE, NUDE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE;

MUS;

EID: 48349102690     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.07.004     Document Type: Article

References (57)

1. Bulte J.W., Douglas T., Witwer B., Zhang S.C., Strable E., Lewis B.K., et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 19 (2001) 1141-1147
2. Olsvik O., Popovic T., Skjerve E., Cudjoe K.S., Hornes E., Ugelstad J., et al. Magnetic separation techniques in diagnostic microbiology. Clin Microbiol Rev 7 (1994) 43-54
3. Scherer F., Anton M., Schillinger U., Henke J., Bergemann C., Kruger A., et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9 (2002) 102-109
4. Wang Y.X., Hussain S.M., and Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11 (2001) 2319-2331
5. Johannsen M., Gneveckow U., Eckelt L., Feussner A., Waldofner N., Scholz R., et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21 (2005) 637-647
6. Alexiou C., Arnold W., Klein R.J., Parak F.G., Hulin P., Bergemann C., et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60 (2000) 6641-6648
7. Lubbe A.S., Bergemann C., Riess H., Schriever F., Reichardt P., Possinger K., et al. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56 (1996) 4686-4693
8. Huh Y.M., Jun Y.W., Song H.T., Kim S., Choi J.S., Lee J.H., et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 127 (2005) 12387-12391
9. Medarova Z., Pham W., Kim Y., Dai G.P., and Moore A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 118 (2006) 2796-2802
10. Gibaldi M. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker Inc, New York, NY
11. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307 (2006) 93-102
12. Stolnik S., Illum L., and Davis S.S. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16 (1995) 195-214
13. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55 (1995) 3752-3756
14. Vijayaraghavalu S., Raghavan D., and Labhasetwar V. Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr Opin Investig Drugs 8 (2007) 477-484
15. Bulte J.W., Brooks R.A., Moskowitz B.M., Bryant Jr. L.H., and Frank J.A. Relaxometry and magnetometry of the MR contrast agent MION-46L. Magn Reson Med 42 (1999) 379-384
16. Jung C.W., and Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 13 (1995) 661-674
17. Okon E., Pouliquen D., Okon P., Kovaleva Z.V., Stepanova T.P., Lavit S.G., et al. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest 71 (1994) 895-903
18. Kohler N., Sun C., Fichtenholtz A., Gunn J., Fang C., and Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2 (2006) 785-792
19. Arias J.L., Ruiz M.A., Gallardo V., and Delgado A.V. Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles. J Controlled Release 125 (2008) 50-58
20. Kim S.Y., and Lee Y.M. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. Biomaterials 22 (2001) 1697-1704
21. Chouly C., Pouliquen D., Lucet I., Jeune J.J., and Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 13 (1996) 245-255
22. 2 based production of magnetically responsive micro- and nanoparticles for drug targeting. Ind Eng Chem Res 41 (2002) 6049-6058
23. Ramirez L.P., and Landfester K. Magnetic polystyrene nanoparticles with a high magnetite content obtained by miniemulsion processes. Macromol Chem Phys 204 (2003) 22-31
24. Dresco P.A., Zaitsev V.S., Gambino R.J., and Chu B. Preparation and properties of magnetite and polymer magnetite nanoparticles. Langmuir 15 (1999) 1945-1951
25. Liu X.Q., Novosad V., Rozhkova E.A., Chen H.T., Yefremenko V., Pearson J., et al. Surface functionalized biocompatible magnetic nanospheres for cancer hyperthermia. IEEE Trans Magn 43 (2007) 2462-2464
26. Hamoudeh M., Al Faraj A., Canet-Soulas E., Bessueille F., Leonard D., and Fessi H. Elaboration of PLLA-based superparamagnetic nanoparticles: characterization, magnetic behaviour study and in vitro relaxivity evaluation. Int J Pharm 338 (2007) 248-257
27. Kubo T., Sugita T., Shimose S., Nitta Y., Ikuta Y., and Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18 (2001) 121-125
28. Zhang J.Q., Zhang Z.R., Yang H., Tan Q.Y., Qin S.R., and Qiu X.L. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res 22 (2005) 573-583
29. Dandamudi S., and Campbell R.B. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28 (2007) 4673-4683
30. Jain T.K., Morales M.A., Sahoo S.K., Leslie-Pelecky D.L., and Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2 (2005) 194-205
31. D'Arpa P., and Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989 (1989) 163-177
32. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
33. Honore S., Pasquier E., and Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62 (2005) 3039-3056
34. Jeffery G.H., Bassett J., Mendham J., and Denny R.C. Vogel's text book of quantitative chemical analysis. 5th ed. (1989), John Wiley & Sons Inc, New York p. 690-92
35. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image Processing with ImageJ. Biophotonics Int 11 (2004) 36-42
36. Yolles S., Aslund B., Morton J.F., Olson O.T., and Rosenberg B. Timed-released depot for anticancer agents. II. Acta Pharm Suec 15 (1978) 382-388
37. Moffat B.A., Reddy G.R., McConville P., Hall D.E., Chenevert T.L., Kopelman R.R., et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2 (2003) 324-332
38. Chou T.C., and Talalay P. Analysis of combined drug effects - a new look at a very old problem. Trends Pharmacol Sci 4 (1983) 450-454
39. Niethammer A., Gaedicke G., Lode H.N., and Wrasidlo W. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjug Chem 12 (2001) 414-420
40. Hansch C., and Leo A. Exploring QSAR (1995), American Chemical Society, Washington, DC
41. Gottlieb J., Lefrak E., O'Brien P., and Burgess M. Fatal adriamycin cardiomyopathy: prevention by dose limitation. Proc Am Assoc Cancer Res 14 (1973) 88
42. Lefrak E.A., Pitha J., Rosenheim S., and Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32 (1973) 302-314
43. Rinehart J.J., Lewis R.P., and Balcerzak S.P. Adriamycin cardiotoxicity in man. Ann Intern Med 81 (1974) 475-478
44. Links M., and Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999 (1999) 1-21
45. Krishna R., and Mayer L. Applications of liposome technology to overcome multidrug resistance in solid tumors. In: Gregoriadis G., and McCormack B. (Eds). Targeting of drugs 6: strategies for stealth therapeutic systems (1998), NATO ASI Series, Plenum Press, New York 95-108
46. 4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res A 80A (2007) 852-860
47. Rudge S.R., Kurtz T.L., Vessely C.R., Catterall L.G., and Williamson D.L. Preparation, characterization, and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomaterials 21 (2000) 1411-1420
48. Westbrook C., Roth C.K., and Talbol J. MRI in practice. 3rd ed. (2005), Blackwell Publishing Inc., Malden, MA
49. Okuhata Y. Delivery of diagnostic agents for magnetic resonance imaging. Adv Drug Deliv Rev 37 (1999) 121-137
50. Moghimi S.M., Muir I.S., Illum L., Davis S.S., and Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1179 (1993) 157-165
51. Storm G., Belliot S.O., Daemen T., and Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17 (1995) 31-48
52. Tan J.S., Butterfield D.E., Voycheck C.L., Caldwell K.D., and Li J.T. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 14 (1993) 823-833
53. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 (1986) 6387-6392
54. Gerlowski L.E., and Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31 (1986) 288-305
55. Jordan A., Scholz R., Wust P., Fahling H., and Felix R. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater 201 (1999) 413-419
56. Urano M., Kuroda M., and Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15 (1999) 79-107
57. Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 3 (2002) 487-497